相关实验视频

Updated: Jul 22, 2025

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

选择性抑制乙型肝炎病毒内部化由氧衍生物的选择性抑制

Mizuki Oshima¹, Frank Stappenbeck², Hirofumi Ohashi³

¹Department of Virology II, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan; Department of Applied Biological Sciences, Tokyo University of Science, Noda, 278-8510, Japan.

Biochemical and biophysical research communications

|July 20, 2023

概括

一种新的化合物Oxy185通过防止病毒进入肝细胞,有效地阻止乙型肝炎病毒 (HBV) 感染. 这种新的机制为开发新的HBV疗法提供了一个有前途的战略.

科学领域:

肝病学肝病学是一种肝病学.
病毒学病毒学
药物发现药物发现药物发现

背景情况:

目前的乙型肝炎病毒 (HBV) 治疗抑制了复制,但没有消除病毒.
具有独特机制的新型抗病毒药物对于HBV根除至关重要.

研究的目的:

为了识别和描述HBV进入的新型抑制剂.
为了研究潜在的HBV进入抑制剂的作用机制.

主要方法:

使用HepG2细胞系和人类原发性肝细胞查化合物.
评估病毒内部化,附着和复制的情况.
与HBV输入受体甲酸携带输送聚 (NTCP) 的相互作用研究.
在小鼠体内体内的药理动力学研究.

主要成果:

一种半合成的氧化醇Oxy185显示出强大的HBV感染抑制作用.
Oxy185通过干扰NTCP寡合化,专门阻止了HBV内部化.
该化合物对HBV表现出泛基因型活性,并抑制了D型肝炎病毒感染.
在小鼠口服后,Oxy185表现出有利的肝脏积累.

结论:

Oxy185代表了一种新的HBV入口抑制剂类别,其向NTCP介导的病毒内化.
这种化合物作为进一步研究HBV进入抑制策略的宝贵工具.
Oxy185有可能开发新的治疗药物来治疗慢性HBV感染.

关键词:

抗病毒药物是一种抗病毒药.进入进入进入这是HBV的HBV.在这里,我们可以看到HDV HDV.在NTCP中,NTCP是NTCP.氧化胆固醇是一种氧化醇.

更多相关视频

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

相关概念视频

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...